Taking a somewhat different approach to addressing heart failure, BioCardia (originally OTCQB:BCADA) - now OTC:BCDA) were also creative in how they achieved Publicly traded status. Having unsuccessfully attempted an IPO in the very difficult market of 2015, the following year (2016) the firm did a reverse merger with publicly traded TigerX Medical previouly dba Cardio Medical. By introducing patient screening and highly-efficient delivery to stem cell therapy, BioCardia has sought to engage clinical-stage regenerative medicine - developing novel therapeutics for cardiovascular diseases with large unmet medical needs. BioCardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its CardiAMP and CardiALLO therapies. Clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived from mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, the firm offers the Helix biotherapeutic delivery system; and Morph vascular access product line, which provides catheter products.
